The prevalence and characteristics of REM sleep behavior disorder in progressive supranuclear palsy patients.
Objective: To describe the prevalence and characteristics of RBD in patients diagnosed with PSP and to demonstrate the association with each PSP subtype. Background: Rapid…Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson’s Disease
Objective: To evaluate baseline CSF and blood-based biomarkers of pathology in early-stage Parkinson’s Disease (PD) participants in the phase 2 clinical trial PASADENA. Background: Observational…Detection of Levodopa induced Dyskinesia based on spectral features from subthalamic-LFP and sensorimotor-ECoG
Objective: To detect the presence of Levodopa induced Dyskinesia (LID) in Parkinson’s disease (PD) patients based on spectral characteristics from invasive cortico-subthalamic recordings using machine…Comparative efficacy of pharmacological cognitive treatments in Parkinson’s disease and Dementia of Lewy Bodies: systemic review & network meta-analysis
Objective: The aim of this study is to evaluate, compare and rank the currently available pharmacological cognitive treatments. Background: Treating cognitive impairment in Parkinson’s disease…Dopamine dysfunction in nigro-striatal pathway—multi-axial pathology in SCA 12
Objective: To assert pathophysiology in spinocerebellar ataxia type 12 (SCA12) extends way beyond cerebellar or spinal pathology. To further sensitise scientific community about consistent nigro-striatal…Exploring patient-physician communication in Parkinson’s disease management: a qualitative analysis
Objective: To explore the unmet needs in patient-physician communication from different perspective.To explore the unmet needs in patient-physician communication from different perspective. Background: Patient-physician communication…Data-driven Clustering of Neurodegenerative diseases based on EEG Spectrum power-law decay: the DaCNES Study.
Objective: To test accuracy of the power law exponent β applied to EEG in differentiating neurodegenerative diseases and to explore differences in neuronal connectivity among…PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…An analysis of gender differences in the clinical profile of Parkinson’s Disease patients
Objective: The present study aimed at characterising in depth the overall clinical profile of male and females PD patients. Background: Parkinson Disease (PD) is the…Cholinergic deficits in Parkinson Disease
Objective: To determine whether loss of cholinergic projections to cortical and limbic regions contributes to the development of dementia in Parkinson’s disease (PD). Background: PD…
- « Previous Page
- 1
- …
- 174
- 175
- 176
- 177
- 178
- …
- 186
- Next Page »